What Is Pramlintide Used For? Approved Uses, Per the Label

The short answer

Pramlintide is a prescription medicine in the United States, approved by the Food and Drug Administration and marketed as Symlin and SymlinPen (pramlintide acetate injection). It is a synthetic analog of the pancreatic hormone amylin, which is co-secreted with insulin by beta cells. Reviews of amylin biology have described pramlintide as the first amylin receptor agonist to reach clinical approval (PMID 41708975).

The approved answer to "what is pramlintide used for" is narrow. Per the US prescribing information, pramlintide is indicated as an adjunctive treatment used with mealtime insulin in patients with type 1 or type 2 diabetes mellitus who have failed to achieve desired glucose control despite optimal insulin therapy. Everything else described in the literature, including obesity research and combination regimens, sits outside that indication.

The approved indications, as the label frames them

The label frames pramlintide as an add-on to existing mealtime insulin rather than a stand-alone glucose-lowering agent. Two populations appear in that indication statement:

Three features of that wording matter for anyone reading the label:

• It is adjunctive. The indication presumes insulin is already in place and continues. Pramlintide is positioned alongside mealtime insulin, not instead of it.
• It is conditioned on prior inadequate control. The indication applies to patients who have not reached their glucose targets despite optimal insulin therapy, not to every insulin user.
• It names two diabetes types and no other condition. Weight management, obesity without diabetes and metabolic syndrome do not appear as approved indications.

The exact sentence structure of the indication has been edited across label revisions, and the review literature cited on this page does not reproduce the current prescribing information verbatim or state its revision month and year. The authoritative source for the present wording is the current Symlin and SymlinPen prescribing information itself, available through FDA labeling databases.

Boxed warning context on the same label

The pramlintide label carries a boxed warning concerning severe hypoglycemia when the medicine is used with insulin, with particular emphasis on type 1 diabetes. That warning sits beside the indication and shapes how the product is prescribed. Review articles on type 1 diabetes pharmacotherapy have likewise reported that the risk of insulin-associated hypoglycemia is the central safety consideration with pramlintide as an insulin adjunct (PMID 30892094). Decisions about whether this warning makes the medicine appropriate for a given person belong with a prescribing clinician.

Regulatory history of the indication

Pramlintide moved through clinical development in the late 1990s and early 2000s. A 2001 review of new pharmacologic agents for diabetes described pramlintide among the agents then under investigation as an addition to insulin therapy, before any approval existed (PMID 12643107). The medicine received FDA approval in 2005 as Symlin, an injectable amylin analog indicated as an adjunct to mealtime insulin in type 1 and type 2 diabetes. A pen-injector presentation, SymlinPen, followed the original vial presentation.

Since approval, the indication itself has remained anchored to insulin-treated diabetes. Label revisions have addressed presentation, administration instructions and safety language rather than adding new diseases. A 2026 account of amylin research placed pramlintide as the clinical proof of concept that amylin receptor agonism could be translated into an approved therapy, with later amylin analogs built on that foundation (PMID 41708975).

What the published literature reports about the evidence base

The pivotal registration trials for pramlintide are summarized in the prescribing information. The peer-reviewed sources cited on this page are reviews rather than the individual pivotal trial reports, so the descriptions below reflect how review authors characterized the accumulated trial evidence, not primary trial results extracted here.

Type 1 diabetes

A 2021 clinical review of type 1 diabetes management reported that pramlintide is an injectable adjunct used alongside insulin in type 1 diabetes rather than a substitute for it (PMID 33970586). A review of pharmacologic options in type 1 diabetes similarly reported that pramlintide is the adjunctive agent that has carried formal approval for use with insulin in this population, while other adjuncts have been studied without that status (PMID 30892094). A 2025 review of insulin resistance in type 1 diabetes discussed pramlintide among the non-insulin agents evaluated as additions to insulin regimens in this population (PMID 39998445).

Type 2 diabetes and the mealtime insulin setting

Because the label indication is tied to mealtime insulin rather than to diabetes type alone, the relevant evidence concerns postprandial glucose. Reviews of amylin physiology reported that amylin receptor agonism slows gastric emptying and suppresses postprandial glucagon secretion, the two mechanisms through which pramlintide blunts the rise in glucose after meals (PMID 41708975). A review of alpha-cell targeting in diabetes reported that suppression of inappropriate glucagon release is a recognized therapeutic strategy and listed amylin agonism among the approaches that act on that axis (PMID 36108978).

Mechanism as described in preclinical work

Preclinical studies help explain why an amylin analog affects appetite as well as glucose. A 2015 study reported that hypothalamic amylin signaling acted in concert with leptin to regulate food intake in rodents (PMID 26655697). Medicinal chemistry work on bio-conjugated amylinomimetic peptides reported preclinical evaluation of long-acting amylin receptor agonists designed to extend the short duration of action associated with native amylin pharmacology (PMID 35436670). Those are mechanistic and preclinical findings, not approved indications.

Adverse Events in Pramlintide Studies: What Studies Report

Review authors have consistently reported two categories of adverse events associated with pramlintide.

• Gastrointestinal effects. A 2021 review of amylin as an obesity target reported that nausea was the most frequently described adverse effect of pramlintide and that it was linked to the delay in gastric emptying produced by amylin receptor agonism (PMID 34929674).
• Hypoglycemia in combination with insulin. A review of pharmacologic treatment options in type 1 diabetes reported that the principal safety concern with insulin adjuncts such as pramlintide is severe hypoglycemia arising from the combination with insulin (PMID 30892094). A review of pharmacological approaches to obesity in type 1 diabetes likewise reported that hypoglycemia risk and tolerability shape how adjunct agents are evaluated in insulin-treated patients (PMID 32618631).

The prescribing information remains the controlling source for the complete adverse reaction profile, contraindications and warnings. Individual risk assessment is a matter for a prescribing clinician.

One factual note on uses that are not approved

Published work has examined pramlintide and other amylin receptor agonists in contexts outside the approved indication, including body weight in obesity and combination regimens. A 2018 review of combination therapies for obesity discussed pramlintide combined with a leptin analog among investigational combinations evaluated for weight reduction (PMID 29993319), a 2021 review discussed amylin agonism as a future obesity treatment strategy (PMID 34929674), a 2017 review of obesity drug targets listed amylin receptors among targets under study (PMID 28245771), and a 2020 review examined pharmacological strategies for obesity in type 1 diabetes (PMID 32618631). None of these represents an approved indication for pramlintide. They are described here as research literature only.

Reading the label for yourself

For anyone trying to establish what a prescription medicine is approved for, the sequence is straightforward:

1. Identify the branded product and manufacturer: Symlin and SymlinPen contain pramlintide acetate.
2. Locate the current FDA-approved prescribing information for that product and note the revision date printed on it.
3. Read Section 1, Indications and Usage, which contains the approved uses in full.
4. Read the boxed warning, contraindications and warnings sections, which modify how the indication is applied in practice.
5. Take any questions about personal applicability, alternatives or risk to a licensed prescribing clinician.

Review articles, including those cited above, summarize clinical context and mechanism. They do not substitute for the indication statement on the label, and they sometimes describe research applications that the label does not cover.

Questions a prescribing clinician is positioned to answer

• Whether an insulin regimen meets the label condition of optimal insulin therapy with glucose control still below target.
• How an amylin analog interacts with existing medicines, including insulin and agents that affect gastric emptying.
• What monitoring is appropriate given the boxed warning on severe hypoglycemia.
• Whether published findings in type 1 diabetes reviews (PMID 33970586) apply to a specific clinical situation.

This page is for educational purposes only and is not medical advice; consult a licensed physician or other qualified prescribing clinician about any medicine, including pramlintide, and about whether any published finding applies to a particular person.

References

• The story of amylin: from physiology to therapy (Nature Metabolism, 2026)
• Diabetes: Type 1 Diabetes (FP Essentials, 2021)
• Pharmacologic treatment options for type 1 diabetes: what's new? (Expert Review of Clinical Pharmacology, 2019)
• Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance (Endocrine Reviews, 2025)
• New pharmacologic agents for diabetes (Current Diabetes Reports, 2001)
• Alpha-cells and therapy of diabetes: Inhibition, antagonism or death? (Peptides, 2022)
• Hypothalamic Amylin Acts in Concert with Leptin to Regulate Food Intake (Cell Metabolism, 2015)
• Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists (European Journal of Medicinal Chemistry, 2022)
• Amylin as a Future Obesity Treatment (Journal of Obesity & Metabolic Syndrome, 2021)
• Combination Therapies for Obesity (Metabolic Syndrome and Related Disorders, 2018)
• Current Drug Targets in Obesity Pharmacotherapy: A Review (Current Drug Targets, 2017)
• Pharmacological therapies to address obesity in type 1 diabetes (Current Opinion in Endocrinology, Diabetes, and Obesity, 2020)